SCHEDULE: Balyasny Asset Management Reports Stake in Quince Therapeutics

Balyasny Asset Management L.P. and affiliated entities have reported beneficial ownership of 9.99% of Quince Therapeutics, Inc. common stock as of June 30, 2026.

Summary

• Balyasny Asset Management L.P. and its related entities (BAM GP LLC, Balyasny Asset Management Holdings LP, Dames GP LLC, and Dmitry Balyasny) have filed a Schedule 13G.
• This filing indicates they beneficially own 97,699 shares of Quince Therapeutics, Inc. common stock.
• This ownership represents 9.99% of the class of securities outstanding as of June 29, 2026.
• The reported shares include directly held shares and shares issuable from the exercise of warrants and preferred shares, subject to a beneficial ownership limitation.
• The filing asserts that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without disclosing specific strategic actions or financial performance.

Positives

• The reporting entities hold a significant stake, indicating confidence or strategic interest in Quince Therapeutics.
• The filing confirms that the ownership is in the ordinary course of business, suggesting no immediate hostile intent.

Negatives

• The filing does not provide any information on the company's financial performance or strategic direction.
• The beneficial ownership limitation on warrants and preferred shares may restrict future increases in stake without further action.

Risks

• Potential for increased trading activity by the reporting entities, which could influence share price volatility.
• The beneficial ownership limitation could lead to complex adjustments if the company's outstanding shares change significantly.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Quince Therapeutics' future performance or strategy.

Management Comments

• "By virtue of its position as the investment manager of Atlas Diversified Master Fund, Ltd. ("ADMF"), the direct holder of the 69,281 shares of common stock... BAM may be deemed to exercise voting and investment power over such shares... and thus may be deemed to beneficially own such shares."
• "Each of the Reporting Persons has the sole power to vote or to direct the vote of 97699 shares."
• "Each of the Reporting Persons has the sole power to dispose or to direct the disposition of 97699 shares."
• "I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities..."

Industry Context

StockSavvy.ai notes that Schedule 13G filings typically indicate passive investment stakes by institutional investors. The 9.99% threshold is often maintained to avoid triggering more stringent reporting requirements associated with active control.

Comparison to Industry Standards

• Institutional investors commonly acquire stakes in the range of 5-10% in publicly traded companies, particularly in the biotechnology and pharmaceutical sectors, to gain exposure without triggering control-related disclosures.
• The structure of the reporting entities (LP, LLC, individual) is typical for asset management firms managing multiple funds and vehicles.
• The use of warrants and preferred shares, along with a beneficial ownership limitation, is a common feature in venture capital and private equity investments, often seen in early-stage or growth companies like Quince Therapeutics.

Stakeholder Impact

• Shareholders: May observe increased market interest or potential price fluctuations due to the reporting of a significant stake by an institutional investor.
• Management of Quince Therapeutics: Will be aware of the increased ownership by Balyasny Asset Management, though the filing indicates a passive intent.

Next Steps

• Continued monitoring of Quince Therapeutics' stock performance and any further filings by Balyasny Asset Management or other significant shareholders.
• Potential for Balyasny Asset Management to adjust its stake, subject to beneficial ownership limitations and market conditions.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, Quince Therapeutics, Balyasny Asset Management, Investment Management, Common Stock, Warrants, Preferred Shares